{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:53:57Z","timestamp":1787961237433,"version":"build-2784847793"},"reference-count":79,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"6","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Stimulant use disorder (SUD) is a public health problem in the United States that is associated with increased morbidity and mortality. Psychosocial interventions, such as cognitive behavioral therapy and contingency management, are the main treatment modality for SUDs and no pharmacotherapy is currently FDA approved for this indication. Although some medications show promising data for the treatment of SUD, the evidence remains inconsistent, and the clinical application is limited due to the heterogenicity of the population and the lack of studies in patients with various comorbidities. Selection of pharmacotherapy treatment for methamphetamine intoxication, persistent methamphetamine-associated psychosis with methamphetamine use disorder, and cocaine use disorder in patients with co-occurring OUD are discussed in 3 patient cases.<\/jats:p>","DOI":"10.9740\/mhc.2021.11.347","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T16:35:39Z","timestamp":1636389339000},"page":"347-357","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacotherapy treatment of stimulant use disorder"],"prefix":"10.9740","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8527-9319","authenticated-orcid":true,"given":"Mei T.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"2021110821353247200_i2168-9709-11-6-347-b01","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association.\n          Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed.\n\t\t\t\t\tArlington (VA):\n\t\t\t\t\tAmerican Psychiatric Publishing;2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2021110821353247200_i2168-9709-11-6-347-b02","doi-asserted-by":"crossref","unstructured":"Siefried\n              KJ,\n            \n            \n              Acheson\n              LS,\n            \n            \n              Lintzeris\n              N,\n            \n            \n              Ezard\n              N.\n            \n          \n          Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review.\n\t\t\t\t\tCNS Drugs.\n\t\t\t\t\t2020;\n\t\t\t\t\t34(4):\n\t\t\t\t\t337-\n\t\t\t\t\t65.\n\t\t\t\t\tDOI: 10.1007\/s40263-020-00711-x. PubMed PMID: 32185696; PubMed Central PMCID: PMC7125061.","DOI":"10.1007\/s40263-020-00711-x"},{"key":"2021110821353247200_i2168-9709-11-6-347-b03","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA).\n          Treatment of stimulant use disorders.\n\t\t\t\t\tSAMHSA Publication No. PEP20-06-01-001.\n\t\t\t\t\tRockville (MD):\n\t\t\t\t\tSAMHSA;\n\t\t\t\t\t2020."},{"key":"2021110821353247200_i2168-9709-11-6-347-b04","doi-asserted-by":"crossref","unstructured":"Farrell\n              M,\n            \n            \n              Martin\n              NK,\n            \n            \n              Stockings\n              E,\n            \n            \n              B\u00f3rquez\n              A,\n            \n            \n              Cepeda\n              JA,\n            \n            \n              Degenhardt\n              L,\n            \n            et al.\n          \n          Responding to global stimulant use: challenges and opportunities.\n\t\t\t\t\tLancet.\n\t\t\t\t\t2019;\n\t\t\t\t\t394(10209):\n\t\t\t\t\t1652-\n\t\t\t\t\t67.\n\t\t\t\t\tDOI: 10.1016\/S0140-6736(19)32230-5. PubMed PMID: 31668409.","DOI":"10.1016\/S0140-6736(19)32230-5"},{"key":"2021110821353247200_i2168-9709-11-6-347-b05","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality.\n          Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. HHS Publication No. PEP19-5068, NSDUH Series H-54.\n\t\t\t\t\tRockville (MD):\n\t\t\t\t\tSAMHSA;2019."},{"key":"2021110821353247200_i2168-9709-11-6-347-b06","doi-asserted-by":"crossref","unstructured":"Zarrabi\n              H,\n            \n            \n              Khalkhali\n              M,\n            \n            \n              Hamidi\n              A,\n            \n            \n              Ahmadi\n              R,\n            \n            \n              Zavarmousavi\n              M.\n            \n          \n          Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients.\n\t\t\t\t\tBMC Psychiatry.\n\t\t\t\t\t2016;\n\t\t\t\t\t16:\n\t\t\t\t\t44.\n\t\t\t\t\tDOI: 10.1186\/s12888-016-0745-5. PubMed PMID: 26911516.","DOI":"10.1186\/s12888-016-0745-5"},{"key":"#cr-split#-2021110821353247200_i2168-9709-11-6-347-b07.1","unstructured":"NIDA.  Behavioral therapies.  National Institute on Drug Abuse[updated 2020 Jun 1"},{"key":"#cr-split#-2021110821353247200_i2168-9709-11-6-347-b07.2","unstructured":"cited 2021 Jan 9].https:\/\/www.drugabuse.gov\/publications\/principles-drug-addiction-treatment-research-based-guide-third-edition\/evidence-based-approaches-to-drug-addiction-treatment\/behavioral-therapies"},{"key":"2021110821353247200_i2168-9709-11-6-347-b08","doi-asserted-by":"crossref","unstructured":"Ronsley\n              C,\n            \n            \n              Nolan\n              S,\n            \n            \n              Knight\n              R,\n            \n            \n              Hayashi\n              K,\n            \n            \n              Klimas\n              J,\n            \n            \n              Walley\n              A,\n            \n            et al.\n          \n          Treatment of stimulant use disorder: a systematic review of reviews.\n\t\t\t\t\tPLoS One.\n\t\t\t\t\t2020;\n\t\t\t\t\t15(6):\n\t\t\t\t\te0234809.\n\t\t\t\t\tDOI: 10.1371\/journal.pone.0234809. PubMed PMID: 32555667.","DOI":"10.1371\/journal.pone.0234809"},{"key":"2021110821353247200_i2168-9709-11-6-347-b09","unstructured":"Chan\n              B,\n            \n            \n              Kondo\n              K,\n            \n            \n              Ayers\n              C,\n            \n            \n              Freeman\n              M,\n            \n            \n              Montgomery\n              J,\n            \n            \n              Paynter\n              R,\n            \n            et al.\n          \n          Pharmacotherapy for stimulant use disorders: a systematic review\n          [Internet].\n          Washington:\n\t\t\t\t\tDepartment of Veterans Affairs (US);\n\t\t\t\t\t2018.\n\t\t\t\t\tPubMed PMID: 30715830."},{"key":"2021110821353247200_i2168-9709-11-6-347-b10","doi-asserted-by":"crossref","unstructured":"Chan\n              B,\n            \n            \n              Freeman\n              M,\n            \n            \n              Kondo\n              K,\n            \n            \n              Ayers\n              C,\n            \n            \n              Montgomery\n              J,\n            \n            \n              Paynter\n              R,\n            \n            et al.\n          \n          Pharmacotherapy for methamphetamine\/amphetamine use disorder\u2014a systematic review and meta-analysis.\n\t\t\t\t\tAddiction.\n\t\t\t\t\t2019;\n\t\t\t\t\t114(12):\n\t\t\t\t\t2122-\n\t\t\t\t\t36.\n\t\t\t\t\tDOI: 10.1111\/add.14755. PubMed PMID: 31328345.","DOI":"10.1111\/add.14755"},{"key":"2021110821353247200_i2168-9709-11-6-347-b11","doi-asserted-by":"crossref","unstructured":"Wodarz\n              N,\n            \n            \n              Krampe-Scheidler\n              A,\n            \n            \n              Christ\n              M,\n            \n            \n              Fleischmann\n              H,\n            \n            \n              Looser\n              W,\n            \n            \n              Schoett\n              K,\n            \n            et al.\n          \n          Evidence-based guidelines for the pharmacological management of acute methamphetamine-related disorders and toxicity.\n\t\t\t\t\tPharmacopsychiatry.\n\t\t\t\t\t2017;\n\t\t\t\t\t50(3):\n\t\t\t\t\t87-\n\t\t\t\t\t95.\n\t\t\t\t\tDOI: 10.1055\/s-0042-123752. PubMed PMID: 28297728.","DOI":"10.1055\/s-0042-123752"},{"key":"2021110821353247200_i2168-9709-11-6-347-b12","doi-asserted-by":"crossref","unstructured":"Connors\n              NJ,\n            \n            \n              Alsakha\n              A,\n            \n            \n              Larocque\n              A,\n            \n            \n              Hoffman\n              RS,\n            \n            \n              Landry\n              T,\n            \n            \n              Gosselin\n              S.\n            \n          \n          Antipsychotics for the treatment of sympathomimetic toxicity: A systematic review.\n\t\t\t\t\tAm J Emerg Med.\n\t\t\t\t\t2019;\n\t\t\t\t\t37(10):\n\t\t\t\t\t1880-\n\t\t\t\t\t90.\n\t\t\t\t\tDOI: 10.1016\/j.ajem.2019.01.001. PubMed PMID: 30639129.","DOI":"10.1016\/j.ajem.2019.01.001"},{"key":"2021110821353247200_i2168-9709-11-6-347-b13","doi-asserted-by":"crossref","unstructured":"Isoardi\n              KZ,\n            \n            \n              Ayles\n              SF,\n            \n            \n              Harris\n              K,\n            \n            \n              Finch\n              CJ,\n            \n            \n              Page\n              CB.\n            \n          \n          Methamphetamine presentations to an emergency department: management and complications.\n\t\t\t\t\tEmerg Med Australas.\n\t\t\t\t\t2019;\n\t\t\t\t\t31(4):\n\t\t\t\t\t593-\n\t\t\t\t\t599.\n\t\t\t\t\tDOI: 10.1111\/1742-6723.13219. PubMed PMID: 30592564.","DOI":"10.1111\/1742-6723.13219"},{"key":"2021110821353247200_i2168-9709-11-6-347-b14","unstructured":"Alam Mehrjerdi\n              Z,\n            \n            \n              Noroozi\n              A.\n            \n          \n          Methamphetamine intoxication in emergency departments of hospitals in Iran: implications for treatment.\n\t\t\t\t\tIran J Med Sci.\n\t\t\t\t\t2013;\n\t\t\t\t\t38(4):\n\t\t\t\t\t347-\n\t\t\t\t\t8.\n\t\t\t\t\tPubMed PMID: 24293791."},{"key":"2021110821353247200_i2168-9709-11-6-347-b15","doi-asserted-by":"crossref","unstructured":"McKetin\n              R,\n            \n            \n              McLaren\n              J,\n            \n            \n              Lubman\n              DI,\n            \n            \n              Hides\n              L.\n            \n          \n          The prevalence of psychotic symptoms among methamphetamine users.\n\t\t\t\t\tAddiction.\n\t\t\t\t\t2006;\n\t\t\t\t\t101(10):\n\t\t\t\t\t1473-\n\t\t\t\t\t8.\n\t\t\t\t\tDOI: 10.1111\/j.1360-0443.2006.01496.x. PubMed PMID: 16968349.","DOI":"10.1111\/j.1360-0443.2006.01496.x"},{"key":"2021110821353247200_i2168-9709-11-6-347-b16","doi-asserted-by":"crossref","unstructured":"Srisurapanont\n              M,\n            \n            \n              Likhitsathian\n              S,\n            \n            \n              Suttajit\n              S,\n            \n            \n              Maneeton\n              N,\n            \n            \n              Maneeton\n              B,\n            \n            \n              Oon-Arom\n              A,\n            \n            et al.\n          \n          Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: a systematic review and network meta-analysis.\n\t\t\t\t\tDrug Alcohol Depend.\n\t\t\t\t\t2021;\n\t\t\t\t\t219:\n\t\t\t\t\t108467.\n\t\t\t\t\tDOI: 10.1016\/j.drugalcdep.2020.108467. PubMed PMID: 33385693.","DOI":"10.1016\/j.drugalcdep.2020.108467"},{"key":"2021110821353247200_i2168-9709-11-6-347-b17","doi-asserted-by":"crossref","unstructured":"Arunogiri\n              S,\n            \n            \n              Foulds\n              JA,\n            \n            \n              McKetin\n              R,\n            \n            \n              Lubman\n              DI.\n            \n          \n          A systematic review of risk factors for methamphetamine-associated psychosis.\n\t\t\t\t\tAust N Z J Psychiatry.\n\t\t\t\t\t2018;\n\t\t\t\t\t52(6):\n\t\t\t\t\t514-\n\t\t\t\t\t29.\n\t\t\t\t\tDOI: 10.1177\/0004867417748750. PubMed PMID: 29338289.","DOI":"10.1177\/0004867417748750"},{"key":"2021110821353247200_i2168-9709-11-6-347-b18","doi-asserted-by":"crossref","unstructured":"Bramness\n              JG,\n            \n            \n              Rognli\n              EB.\n            \n          \n          Psychosis induced by amphetamines.\n\t\t\t\t\tCurr Opin Psychiatry.\n\t\t\t\t\t2016;\n\t\t\t\t\t29(4):\n\t\t\t\t\t236-\n\t\t\t\t\t41.\n\t\t\t\t\tDOI: 10.1097\/YCO.0000000000000254. PubMed PMID: 27175554.","DOI":"10.1097\/YCO.0000000000000254"},{"key":"2021110821353247200_i2168-9709-11-6-347-b19","doi-asserted-by":"crossref","unstructured":"Fasihpour\n              B,\n            \n            \n              Molavi\n              S,\n            \n            \n              Shariat\n              SV.\n            \n          \n          Clinical features of inpatients with methamphetamine-induced psychosis.\n\t\t\t\t\tJ Ment Health.\n\t\t\t\t\t2013;\n\t\t\t\t\t22(4):\n\t\t\t\t\t341-\n\t\t\t\t\t9.\n\t\t\t\t\tDOI: 10.3109\/09638237.2012.745184. PubMed PMID: 23323572.","DOI":"10.3109\/09638237.2012.745184"},{"key":"2021110821353247200_i2168-9709-11-6-347-b20","doi-asserted-by":"crossref","unstructured":"McKetin\n              R,\n            \n            \n              Baker\n              AL,\n            \n            \n              Dawe\n              S,\n            \n            \n              Voce\n              A,\n            \n            \n              Lubman\n              DI.\n            \n          \n          Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders.\n\t\t\t\t\tPsychiatry Res.\n\t\t\t\t\t2017;\n\t\t\t\t\t251:\n\t\t\t\t\t349-\n\t\t\t\t\t54.\n\t\t\t\t\tDOI: 10.1016\/j.psychres.2017.02.028. PubMed PMID: 28282630.","DOI":"10.1016\/j.psychres.2017.02.028"},{"key":"2021110821353247200_i2168-9709-11-6-347-b21","doi-asserted-by":"crossref","unstructured":"Medhus\n              S,\n            \n            \n              Rognli\n              EB,\n            \n            \n              Gossop\n              M,\n            \n            \n              Holm\n              B,\n            \n            \n              M\u00f8rland\n              J,\n            \n            \n              Bramness\n              JG.\n            \n          \n          Amphetamine-induced psychosis: transition to schizophrenia and mortality in a small prospective sample.\n\t\t\t\t\tAm J Addict.\n\t\t\t\t\t2015;\n\t\t\t\t\t24(7):\n\t\t\t\t\t586-\n\t\t\t\t\t9.\n\t\t\t\t\tDOI: 10.1111\/ajad.12274. PubMed PMID: 26332037.","DOI":"10.1111\/ajad.12274"},{"key":"2021110821353247200_i2168-9709-11-6-347-b22","doi-asserted-by":"crossref","unstructured":"Rognli\n              EB,\n            \n            \n              Bramness\n              JG.\n            \n          \n          Understanding the relationship between amphetamines and psychosis.\n\t\t\t\t\tCurr Addict Rep.\n\t\t\t\t\t2015;\n\t\t\t\t\t2(4):\n\t\t\t\t\t285-\n\t\t\t\t\t92.\n\t\t\t\t\tDOI: 10.1007\/s40429-015-0077-4.","DOI":"10.1007\/s40429-015-0077-4"},{"key":"2021110821353247200_i2168-9709-11-6-347-b23","doi-asserted-by":"crossref","unstructured":"Fluyau\n              D,\n            \n            \n              Mitra\n              P,\n            \n            \n              Lorthe\n              K.\n            \n          \n          Antipsychotics for amphetamine psychosis. A systematic review.\n\t\t\t\t\tFront Psychiatry.\n\t\t\t\t\t2019;\n\t\t\t\t\t10:\n\t\t\t\t\t740.\n\t\t\t\t\tDOI: 10.3389\/fpsyt.2019.00740. PubMed PMID: 31681046.","DOI":"10.3389\/fpsyt.2019.00740"},{"key":"2021110821353247200_i2168-9709-11-6-347-b24","unstructured":"Leelahanaj\n              T,\n            \n            \n              Kongsakon\n              R,\n            \n            \n              Netrakom\n              P. A\n            \n          \n          4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis.\n\t\t\t\t\tJ Med Assoc Thai.\n\t\t\t\t\t2005;\n\t\t\t\t\t88Suppl 3:\n\t\t\t\t\tS43-\n\t\t\t\t\t52.\n\t\t\t\t\tPubMed PMID: 16858942."},{"key":"2021110821353247200_i2168-9709-11-6-347-b25","doi-asserted-by":"crossref","unstructured":"Farnia\n              V,\n            \n            \n              Shakeri\n              J,\n            \n            \n              Tatari\n              F,\n            \n            \n              Juibari\n              TA,\n            \n            \n              Yazdchi\n              K,\n            \n            \n              Bajoghli\n              H,\n            \n            et al.\n          \n          Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis.\n\t\t\t\t\tAm J Drug Alcohol Abuse.\n\t\t\t\t\t2014;\n\t\t\t\t\t40(1):\n\t\t\t\t\t10-\n\t\t\t\t\t5.\n\t\t\t\t\tDOI: 10.3109\/00952990.2013.861843. PubMed PMID: 24359506.","DOI":"10.3109\/00952990.2013.861843"},{"key":"2021110821353247200_i2168-9709-11-6-347-b26","doi-asserted-by":"crossref","unstructured":"Verachai\n              V,\n            \n            \n              Rukngan\n              W,\n            \n            \n              Chawanakrasaesin\n              K,\n            \n            \n              Nilaban\n              S,\n            \n            \n              Suwanmajo\n              S,\n            \n            \n              Thanateerabunjong\n              R,\n            \n            et al.\n          \n          Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine.\n\t\t\t\t\tPsychopharmacol (Berl).\n\t\t\t\t\t2014;\n\t\t\t\t\t231(16):\n\t\t\t\t\t3099-\n\t\t\t\t\t108.\n\t\t\t\t\tDOI: 10.1007\/s00213-014-3485-6. PubMed PMID: 24535654.","DOI":"10.1007\/s00213-014-3485-6"},{"key":"2021110821353247200_i2168-9709-11-6-347-b27","doi-asserted-by":"crossref","unstructured":"Samiei\n              M,\n            \n            \n              Vahidi\n              M,\n            \n            \n              Rezaee\n              O,\n            \n            \n              Yaraghchi\n              A,\n            \n            \n              Daneshmand\n              R.\n            \n          \n          Methamphetamine-associated psychosis and treatment with haloperidol and risperidone: a pilot study.\n\t\t\t\t\tIran J Psychiatry Behav Sci.\n\t\t\t\t\t2016;\n\t\t\t\t\t10(3):\n\t\t\t\t\te7988.\n\t\t\t\t\tDOI: 10.17795\/ijpbs-7988. PubMed PMID: 27822286.","DOI":"10.17795\/ijpbs-7988"},{"key":"2021110821353247200_i2168-9709-11-6-347-b28","doi-asserted-by":"crossref","unstructured":"Wang\n              G,\n            \n            \n              Zhang\n              Y,\n            \n            \n              Zhang\n              S,\n            \n            \n              Chen\n              H,\n            \n            \n              Xu\n              Z,\n            \n            \n              Schottenfeld\n              RS,\n            \n            et al.\n          \n          Aripiprazole and risperidone for treatment of methamphetamine-associated psychosis in Chinese patients.\n\t\t\t\t\tJ Subst Abuse Treat.\n\t\t\t\t\t2016;\n\t\t\t\t\t62:\n\t\t\t\t\t84-\n\t\t\t\t\t8.\n\t\t\t\t\tDOI: 10.1016\/j.jsat.2015.11.009. PubMed PMID: 26733277.","DOI":"10.1016\/j.jsat.2015.11.009"},{"key":"2021110821353247200_i2168-9709-11-6-347-b29","doi-asserted-by":"crossref","unstructured":"Wang\n              G,\n            \n            \n              Ding\n              F,\n            \n            \n              Chawarski\n              MC,\n            \n            \n              Hao\n              W,\n            \n            \n              Liu\n              X,\n            \n            \n              Deng\n              Q,\n            \n            et al.\n          \n          Randomized controlled trial of paliperidone extended release versus risperidone for the treatment of methamphetamine-associated psychosis in Chinese patients.\n\t\t\t\t\tFront Psychiatry.\n\t\t\t\t\t2020;\n\t\t\t\t\t11:\n\t\t\t\t\t237.\n\t\t\t\t\tDOI: 10.3389\/fpsyt.2020.00237. PubMed PMID: 32296355; PubMed Central PMCID: PMC7141424.","DOI":"10.3389\/fpsyt.2020.00237"},{"key":"2021110821353247200_i2168-9709-11-6-347-b30","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Revuelta\n              M,\n            \n            \n              Pelayo-Ter\u00e1n\n              JM,\n            \n            \n              Juncal-Ruiz\n              M,\n            \n            \n              V\u00e1zquez-Bourgon\n              J,\n            \n            \n              Su\u00e1rez-Pinilla\n              P,\n            \n            \n              Romero-Jim\u00e9nez\n              R,\n            \n            et al.\n          \n          Antipsychotic treatment effectiveness in first episode of psychosis: PAFIP 3-year follow-up randomized clinical trials comparing haloperidol, olanzapine, risperidone, aripiprazole, quetiapine, and ziprasidone.\n\t\t\t\t\tInt J Neuropsychopharmacol.\n\t\t\t\t\t2020;\n\t\t\t\t\t23(4):\n\t\t\t\t\t217-\n\t\t\t\t\t29.\n\t\t\t\t\tDOI: 10.1093\/ijnp\/pyaa004. PubMed PMID: 31974576; PubMed Central PMCID: PMC7177160.","DOI":"10.1093\/ijnp\/pyaa004"},{"key":"2021110821353247200_i2168-9709-11-6-347-b31","doi-asserted-by":"crossref","unstructured":"Cheng\n              Z,\n            \n            \n              Yuan\n              Y,\n            \n            \n              Han\n              X,\n            \n            \n              Yang\n              L,\n            \n            \n              Cai\n              S,\n            \n            \n              Yang\n              FD,\n            \n            et al.\n          \n          An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: eight-week outcomes.\n\t\t\t\t\tJ Psychopharmacol.\n\t\t\t\t\t2019;\n\t\t\t\t\t33(10):\n\t\t\t\t\t1227-\n\t\t\t\t\t36.\n\t\t\t\t\tDOI: 10.1177\/0269881119872193. PubMed PMID: 31487208.","DOI":"10.1177\/0269881119872193"},{"key":"2021110821353247200_i2168-9709-11-6-347-b32","doi-asserted-by":"crossref","unstructured":"Robinson\n              DG,\n            \n            \n              Gallego\n              JA,\n            \n            \n              John\n              M,\n            \n            \n              Petrides\n              G,\n            \n            \n              Hassoun\n              Y,\n            \n            \n              Zhang\n              J-P,\n            \n            et al.\n          \n          A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes.\n\t\t\t\t\tSchizophr Bull.\n\t\t\t\t\t2015;\n\t\t\t\t\t41(6):\n\t\t\t\t\t1227-\n\t\t\t\t\t36.\n\t\t\t\t\tDOI: 10.1093\/schbul\/sbv125. PubMed PMID: 26338693; PubMed Central PMCID: PMC4601722.","DOI":"10.1093\/schbul\/sbv125"},{"key":"2021110821353247200_i2168-9709-11-6-347-b33","doi-asserted-by":"crossref","unstructured":"Tardelli\n              VS,\n            \n            \n              Bisaga\n              A,\n            \n            \n              Arcadepani\n              FB,\n            \n            \n              Gerra\n              G,\n            \n            \n              Levin\n              FR,\n            \n            \n              Fidalgo\n              TM.\n            \n          \n          Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.\n\t\t\t\t\tPsychopharmacol (Berl).\n\t\t\t\t\t2020;\n\t\t\t\t\t237(8):\n\t\t\t\t\t2233-\n\t\t\t\t\t55.\n\t\t\t\t\tDOI: 10.1007\/s00213-020-05563-3. PubMed PMID: 32601988.","DOI":"10.1007\/s00213-020-05563-3"},{"key":"2021110821353247200_i2168-9709-11-6-347-b34","doi-asserted-by":"crossref","unstructured":"Tiihonen\n              J,\n            \n            \n              Kuoppasalmi\n              K,\n            \n            \n              F\u00f6hr\n              J,\n            \n            \n              Tuomola\n              P,\n            \n            \n              Kuikanm\u00e4ki\n              O,\n            \n            \n              Vorma\n              H,\n            \n            et al.\n          \n          A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence.\n\t\t\t\t\tAm J Psychiatry.\n\t\t\t\t\t2007;\n\t\t\t\t\t164(1):\n\t\t\t\t\t160-\n\t\t\t\t\t2.\n\t\t\t\t\tDOI: 10.1176\/ajp.2007.164.1.160. PubMed PMID: 17202560.","DOI":"10.1176\/ajp.2007.164.1.160"},{"key":"2021110821353247200_i2168-9709-11-6-347-b35","doi-asserted-by":"crossref","unstructured":"Konstenius\n              M,\n            \n            \n              Jayaram-Lindstr\u00f6m\n              N,\n            \n            \n              Guterstam\n              J,\n            \n            \n              Beck\n              O,\n            \n            \n              Philips\n              B,\n            \n            \n              Franck\n              J.\n            \n          \n          Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial.\n\t\t\t\t\tAddiction.\n\t\t\t\t\t2014;\n\t\t\t\t\t109(3):\n\t\t\t\t\t440-\n\t\t\t\t\t9.\n\t\t\t\t\tDOI: 10.1111\/add.12369. PubMed PMID: 24118269.","DOI":"10.1111\/add.12369"},{"key":"2021110821353247200_i2168-9709-11-6-347-b36","doi-asserted-by":"crossref","unstructured":"Stoops\n              WW,\n            \n            \n              Rush\n              CR.\n            \n          \n          Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research.\n\t\t\t\t\tExpert Rev Clin Pharmacol.\n\t\t\t\t\t2014;\n\t\t\t\t\t7(3):\n\t\t\t\t\t363-\n\t\t\t\t\t74.\n\t\t\t\t\tDOI: 10.1586\/17512433.2014.909283. PubMed PMID: 24716825.","DOI":"10.1586\/17512433.2014.909283"},{"key":"2021110821353247200_i2168-9709-11-6-347-b37","doi-asserted-by":"crossref","unstructured":"Elkashef\n              A,\n            \n            \n              Kahn\n              R,\n            \n            \n              Yu\n              E,\n            \n            \n              Iturriaga\n              E,\n            \n            \n              Li\n              S-H,\n            \n            \n              Anderson\n              A,\n            \n            et al.\n          \n          Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial.\n\t\t\t\t\tAddiction.\n\t\t\t\t\t2012;\n\t\t\t\t\t107(7):\n\t\t\t\t\t1297-\n\t\t\t\t\t306.\n\t\t\t\t\tDOI: 10.1111\/j.1360-0443.2011.03771.x. PubMed PMID: 22221594.","DOI":"10.1111\/j.1360-0443.2011.03771.x"},{"key":"2021110821353247200_i2168-9709-11-6-347-b38","doi-asserted-by":"crossref","unstructured":"Jayaram-Lindstr\u00f6m\n              N,\n            \n            \n              Hammarberg\n              A,\n            \n            \n              Beck\n              O,\n            \n            \n              Franck\n              J.\n            \n          \n          Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial.\n\t\t\t\t\tAm J Psychiatry.\n\t\t\t\t\t2008;\n\t\t\t\t\t165(11):\n\t\t\t\t\t1442-\n\t\t\t\t\t8.\n\t\t\t\t\tDOI: 10.1176\/appi.ajp.2008.08020304. PubMed PMID: 18765480.","DOI":"10.1176\/appi.ajp.2008.08020304"},{"key":"2021110821353247200_i2168-9709-11-6-347-b39","doi-asserted-by":"crossref","unstructured":"Runarsdottir\n              V,\n            \n            \n              Hansdottir\n              I,\n            \n            \n              Tyrfingsson\n              T,\n            \n            \n              Einarsson\n              M,\n            \n            \n              Dugosh\n              K,\n            \n            \n              Royer-Malvestuto\n              C,\n            \n            et al.\n          \n          Extended-release injectable naltrexone (XR-NTX) with intensive psychosocial therapy for amphetamine-dependent persons seeking treatment: a placebo-controlled trial.\n\t\t\t\t\tJ Addict Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t11(3):\n\t\t\t\t\t197-\n\t\t\t\t\t204.\n\t\t\t\t\tDOI: 10.1097\/ADM.0000000000000297. PubMed PMID: 28379861; PubMed Central PMCID: PMC5449233.","DOI":"10.1097\/ADM.0000000000000297"},{"key":"2021110821353247200_i2168-9709-11-6-347-b40","doi-asserted-by":"crossref","unstructured":"Coffin\n              PO,\n            \n            \n              Santos\n              G-M,\n            \n            \n              Hern\n              J,\n            \n            \n              Vittinghoff\n              E,\n            \n            \n              Santos\n              D,\n            \n            \n              Matheson\n              T,\n            \n            et al.\n          \n          Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.\n\t\t\t\t\tAddiction.\n\t\t\t\t\t2018;\n\t\t\t\t\t113(2):\n\t\t\t\t\t268-\n\t\t\t\t\t78.\n\t\t\t\t\tDOI: 10.1111\/add.13950. PubMed PMID: 28734107; PubMed Central PMCID: PMC5760469.","DOI":"10.1111\/add.13950"},{"key":"2021110821353247200_i2168-9709-11-6-347-b41","doi-asserted-by":"crossref","unstructured":"Tiihonen\n              J,\n            \n            \n              Krupitsky\n              E,\n            \n            \n              Verbitskaya\n              E,\n            \n            \n              Blokhina\n              E,\n            \n            \n              Mamontova\n              O,\n            \n            \n              F\u00f6hr\n              J,\n            \n            et al.\n          \n          Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial.\n\t\t\t\t\tAm J Psychiatry.\n\t\t\t\t\t2012;\n\t\t\t\t\t169(5):\n\t\t\t\t\t531-\n\t\t\t\t\t6.\n\t\t\t\t\tDOI: 10.1176\/appi.ajp.2011.11071121. PubMed PMID: 22764364.","DOI":"10.1176\/appi.ajp.2011.11071121"},{"key":"2021110821353247200_i2168-9709-11-6-347-b42","doi-asserted-by":"crossref","unstructured":"Colfax\n              GN,\n            \n            \n              Santos\n              G-M,\n            \n            \n              Das\n              M,\n            \n            \n              Santos\n              DM,\n            \n            \n              Matheson\n              T,\n            \n            \n              Gasper\n              J,\n            \n            et al.\n          \n          Mirtazapine to reduce methamphetamine use: a randomized controlled trial.\n\t\t\t\t\tArch Gen Psychiatry.\n\t\t\t\t\t2011;\n\t\t\t\t\t68(11):\n\t\t\t\t\t1168-\n\t\t\t\t\t75.\n\t\t\t\t\tDOI: 10.1001\/archgenpsychiatry.2011.124. PubMed PMID: 22065532; PubMed Central PMCID: PMC3437988.","DOI":"10.1001\/archgenpsychiatry.2011.124"},{"key":"2021110821353247200_i2168-9709-11-6-347-b43","doi-asserted-by":"crossref","unstructured":"Coffin\n              PO,\n            \n            \n              Santos\n              G-M,\n            \n            \n              Hern\n              J,\n            \n            \n              Vittinghoff\n              E,\n            \n            \n              Walker\n              JE,\n            \n            \n              Matheson\n              T,\n            \n            et al.\n          \n          Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial.\n\t\t\t\t\tJAMA Psychiatry.\n\t\t\t\t\t2020;\n\t\t\t\t\t77(3):\n\t\t\t\t\t246-\n\t\t\t\t\t55.\n\t\t\t\t\tDOI: 10.1001\/jamapsychiatry.2019.3655. PubMed PMID: 31825466; PubMed Central PMCID: PMC6990973.","DOI":"10.1001\/jamapsychiatry.2019.3655"},{"key":"2021110821353247200_i2168-9709-11-6-347-b44","doi-asserted-by":"crossref","unstructured":"Shoptaw\n              S,\n            \n            \n              Heinzerling\n              KG,\n            \n            \n              Rotheram-Fuller\n              E,\n            \n            \n              Steward\n              T,\n            \n            \n              Wang\n              J,\n            \n            \n              Swanson\n              A-N,\n            \n            et al.\n          \n          Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence.\n\t\t\t\t\tDrug Alcohol Depend.\n\t\t\t\t\t2008;\n\t\t\t\t\t96(3):\n\t\t\t\t\t222-\n\t\t\t\t\t32.\n\t\t\t\t\tDOI: 10.1016\/j.drugalcdep.2008.03.010. PubMed PMID: 18468815; PubMed Central PMCID: PMC3652530.","DOI":"10.1016\/j.drugalcdep.2008.03.010"},{"key":"2021110821353247200_i2168-9709-11-6-347-b45","doi-asserted-by":"crossref","unstructured":"Elkashef\n              AM,\n            \n            \n              Rawson\n              RA,\n            \n            \n              Anderson\n              AL,\n            \n            \n              Li\n              S-H,\n            \n            \n              Holmes\n              T,\n            \n            \n              Smith\n              EV,\n            \n            et al.\n          \n          Bupropion for the treatment of methamphetamine dependence.\n\t\t\t\t\tNeuropsychopharmacol.\n\t\t\t\t\t2008;\n\t\t\t\t\t33(5):\n\t\t\t\t\t1162-\n\t\t\t\t\t70.\n\t\t\t\t\tDOI: 10.1038\/sj.npp.1301481. PubMed PMID: 17581531.","DOI":"10.1038\/sj.npp.1301481"},{"key":"2021110821353247200_i2168-9709-11-6-347-b46","doi-asserted-by":"crossref","unstructured":"Anderson\n              AL,\n            \n            \n              Li\n              S-H,\n            \n            \n              Markova\n              D,\n            \n            \n              Holmes\n              TH,\n            \n            \n              Chiang\n              N,\n            \n            \n              Kahn\n              R,\n            \n            et al.\n          \n          Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.\n\t\t\t\t\tDrug Alcohol Depend.\n\t\t\t\t\t2015;\n\t\t\t\t\t150:\n\t\t\t\t\t170-\n\t\t\t\t\t4.\n\t\t\t\t\tDOI: 10.1016\/j.drugalcdep.2015.01.036. PubMed PMID: 25818061; PubMed Central PMCID: PMC4388163.","DOI":"10.1016\/j.drugalcdep.2015.01.036"},{"key":"2021110821353247200_i2168-9709-11-6-347-b47","doi-asserted-by":"crossref","unstructured":"Trivedi\n              MH,\n            \n            \n              Walker\n              R,\n            \n            \n              Ling\n              W,\n            \n            \n              dela Cruz\n              A,\n            \n            \n              Sharma\n              G,\n            \n            \n              Carmody\n              T,\n            \n            et al.\n          \n          Bupropion and naltrexone in methamphetamine use disorder.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2021;\n\t\t\t\t\t384(2):\n\t\t\t\t\t140-\n\t\t\t\t\t53.\n\t\t\t\t\tDOI: 10.1056\/NEJMoa2020214. PubMed PMID: 33497547.","DOI":"10.1056\/NEJMoa2020214"},{"key":"2021110821353247200_i2168-9709-11-6-347-b48","doi-asserted-by":"crossref","unstructured":"Cicero\n              TJ,\n            \n            \n              Ellis\n              MS,\n            \n            \n              Kasper\n              ZA.\n            \n          \n          Polysubstance use: a broader understanding of substance use during the opioid crisis.\n\t\t\t\t\tAm J Public Health.\n\t\t\t\t\t2020;\n\t\t\t\t\t110(2):\n\t\t\t\t\t244-\n\t\t\t\t\t50.\n\t\t\t\t\tDOI: 10.2105\/AJPH.2019.305412. PubMed PMID: 31855487.","DOI":"10.2105\/AJPH.2019.305412"},{"key":"2021110821353247200_i2168-9709-11-6-347-b49","doi-asserted-by":"crossref","unstructured":"Chan\n              B,\n            \n            \n              Freeman\n              M,\n            \n            \n              Ayers\n              C,\n            \n            \n              Korthuis\n              PT,\n            \n            \n              Paynter\n              R,\n            \n            \n              Kondo\n              K,\n            \n            et al.\n          \n          A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders.\n\t\t\t\t\tDrug Alcohol Depend.\n\t\t\t\t\t2020;\n\t\t\t\t\t216:\n\t\t\t\t\t108193.\n\t\t\t\t\tDOI: 10.1016\/j.drugalcdep.2020.108193. PubMed PMID: 32861136.","DOI":"10.1016\/j.drugalcdep.2020.108193"},{"key":"2021110821353247200_i2168-9709-11-6-347-b50","doi-asserted-by":"crossref","unstructured":"Chan\n              B,\n            \n            \n              Kondo\n              K,\n            \n            \n              Freeman\n              M,\n            \n            \n              Ayers\n              C,\n            \n            \n              Montgomery\n              J,\n            \n            \n              Kansagara\n              D.\n            \n          \n          Pharmacotherapy for cocaine use disorder\u2014a systematic review and meta-analysis.\n\t\t\t\t\tJ Gen Intern Med.\n\t\t\t\t\t2019;\n\t\t\t\t\t34(12):\n\t\t\t\t\t2858-\n\t\t\t\t\t73.\n\t\t\t\t\tDOI: 10.1007\/s11606-019-05074-8. PubMed PMID: 31183685.","DOI":"10.1007\/s11606-019-05074-8"},{"key":"2021110821353247200_i2168-9709-11-6-347-b51","doi-asserted-by":"crossref","unstructured":"Margolin\n              A,\n            \n            \n              Kosten\n              TR,\n            \n            \n              Avants\n              SK,\n            \n            \n              Wilkins\n              J,\n            \n            \n              Ling\n              W,\n            \n            \n              Beckson\n              M,\n            \n            et al.\n          \n          A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients.\n\t\t\t\t\tDrug Alcohol Depend.\n\t\t\t\t\t1995;\n\t\t\t\t\t40(2):\n\t\t\t\t\t125-\n\t\t\t\t\t31.\n\t\t\t\t\tDOI: 10.1016\/0376-8716(95)01198-6. PubMed PMID: 8745134.","DOI":"10.1016\/0376-8716(95)01198-6"},{"key":"2021110821353247200_i2168-9709-11-6-347-b52","doi-asserted-by":"crossref","unstructured":"Poling\n              J,\n            \n            \n              Oliveto\n              A,\n            \n            \n              Petry\n              N,\n            \n            \n              Sofuoglu\n              M,\n            \n            \n              Gonsai\n              K,\n            \n            \n              Gonzalez\n              G,\n            \n            et al.\n          \n          Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.\n\t\t\t\t\tArch Gen Psychiatry.\n\t\t\t\t\t2006;\n\t\t\t\t\t63(2):\n\t\t\t\t\t219-\n\t\t\t\t\t28.\n\t\t\t\t\tDOI: 10.1001\/archpsyc.63.2.219. PubMed PMID: 16461866.","DOI":"10.1001\/archpsyc.63.2.219"},{"key":"2021110821353247200_i2168-9709-11-6-347-b53","doi-asserted-by":"crossref","unstructured":"Arndt\n              IO.\n            \n          \n          Desipramine treatment of cocaine dependence in methadone-maintained patients.\n\t\t\t\t\tArch Gen Psychiatry.\n\t\t\t\t\t1992;\n\t\t\t\t\t49(11):\n\t\t\t\t\t888-\n\t\t\t\t\t93.\n\t\t\t\t\tDOI: 10.1001\/archpsyc.1992.01820110052008. PubMed PMID: 1444727.","DOI":"10.1001\/archpsyc.1992.01820110052008"},{"key":"2021110821353247200_i2168-9709-11-6-347-b54","doi-asserted-by":"crossref","unstructured":"Kolar\n              AF,\n            \n            \n              Brown\n              BS,\n            \n            \n              Weddington\n              WW,\n            \n            \n              Haertzen\n              CC,\n            \n            \n              Michaelson\n              BS,\n            \n            \n              Jaffe\n              JH.\n            \n          \n          Treatment of cocaine dependence in methadone maintenance clients: a pilot study comparing the efficacy of desipramine and amantadine.\n\t\t\t\t\tInt J Addict.\n\t\t\t\t\t1992;\n\t\t\t\t\t27(7):\n\t\t\t\t\t849-\n\t\t\t\t\t68.\n\t\t\t\t\tDOI: 10.3109\/10826089209068770. PubMed PMID: 1319961.","DOI":"10.3109\/10826089209068770"},{"key":"2021110821353247200_i2168-9709-11-6-347-b55","doi-asserted-by":"crossref","unstructured":"Kosten\n              TR,\n            \n            \n              Morgan\n              CM,\n            \n            \n              Falcione\n              J,\n            \n            \n              Schottenfeld\n              RS.\n            \n          \n          Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine.\n\t\t\t\t\tArch Gen Psychiatry.\n\t\t\t\t\t1992;\n\t\t\t\t\t49(11):\n\t\t\t\t\t894-\n\t\t\t\t\t8.\n\t\t\t\t\tDOI: 10.1001\/archpsyc.1992.01820110058009. PubMed PMID: 1444728.","DOI":"10.1001\/archpsyc.1992.01820110058009"},{"key":"2021110821353247200_i2168-9709-11-6-347-b56","doi-asserted-by":"crossref","unstructured":"Kosten\n              T,\n            \n            \n              Oliveto\n              A,\n            \n            \n              Feingold\n              A,\n            \n            \n              Poling\n              J,\n            \n            \n              Sevarino\n              K,\n            \n            \n              McCance-Katz\n              E,\n            \n            et al.\n          \n          Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients.\n\t\t\t\t\tDrug Alcohol Depend.\n\t\t\t\t\t2003;\n\t\t\t\t\t70(3):\n\t\t\t\t\t315-\n\t\t\t\t\t25.\n\t\t\t\t\tDOI: 10.1016\/s0376-8716(03)00032-2. PubMed PMID: 12757969.","DOI":"10.1016\/S0376-8716(03)00032-2"},{"key":"2021110821353247200_i2168-9709-11-6-347-b57","unstructured":"O'Brien\n              CP,\n            \n            \n              Childress\n              AR,\n            \n            \n              Arndt\n              IO,\n            \n            \n              McLellan\n              AT,\n            \n            \n              Woody\n              GE,\n            \n            \n              Maany\n              I.\n            \n          \n          Pharmacological and behavioral treatments of cocaine dependence: controlled studies.\n\t\t\t\t\tJ Clin Psychiatry.\n\t\t\t\t\t1988;\n\t\t\t\t\t49Suppl:\n\t\t\t\t\t17-\n\t\t\t\t\t22.\n\t\t\t\t\tPubMed PMID: 3276670."},{"key":"2021110821353247200_i2168-9709-11-6-347-b58","doi-asserted-by":"crossref","unstructured":"Oliveto\n              AH,\n            \n            \n              Feingold\n              A,\n            \n            \n              Schottenfeld\n              R,\n            \n            \n              Jatlow\n              P,\n            \n            \n              Kosten\n              TR.\n            \n          \n          Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone.\n\t\t\t\t\tArch Gen Psychiatry.\n\t\t\t\t\t1999;\n\t\t\t\t\t56(9):\n\t\t\t\t\t812-\n\t\t\t\t\t20.\n\t\t\t\t\tDOI: 10.1001\/archpsyc.56.9.812. PubMed PMID: 12884887.","DOI":"10.1001\/archpsyc.56.9.812"},{"key":"2021110821353247200_i2168-9709-11-6-347-b59","doi-asserted-by":"crossref","unstructured":"Grabowski\n              J,\n            \n            \n              Rhoades\n              H,\n            \n            \n              Elk\n              R,\n            \n            \n              Schmitz\n              J,\n            \n            \n              Davis\n              C,\n            \n            \n              Creson\n              D,\n            \n            et al.\n          \n          Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials.\n\t\t\t\t\tJ Clin Psychopharmacol.\n\t\t\t\t\t1995;\n\t\t\t\t\t15(3):\n\t\t\t\t\t163-\n\t\t\t\t\t74.\n\t\t\t\t\tDOI: 10.1097\/00004714-199506000-00004. PubMed PMID: 7635993.","DOI":"10.1097\/00004714-199506000-00004"},{"key":"2021110821353247200_i2168-9709-11-6-347-b60","doi-asserted-by":"crossref","unstructured":"Winstanley\n              EL,\n            \n            \n              Bigelow\n              GE,\n            \n            \n              Silverman\n              K,\n            \n            \n              Johnson\n              RE,\n            \n            \n              Strain\n              EC.\n            \n          \n          A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients.\n\t\t\t\t\tJ Subst Abuse Treat.\n\t\t\t\t\t2011;\n\t\t\t\t\t40(3):\n\t\t\t\t\t255-\n\t\t\t\t\t64.\n\t\t\t\t\tDOI: 10.1016\/j.jsat.2010.11.010. PubMed PMID: 21266301.","DOI":"10.1016\/j.jsat.2010.11.010"},{"key":"2021110821353247200_i2168-9709-11-6-347-b61","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez\n              G,\n            \n            \n              Desai\n              R,\n            \n            \n              Sofuoglu\n              M,\n            \n            \n              Poling\n              J,\n            \n            \n              Oliveto\n              A,\n            \n            \n              Gonsai\n              K,\n            \n            et al.\n          \n          Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients.\n\t\t\t\t\tDrug Alcohol Depend.\n\t\t\t\t\t2007;\n\t\t\t\t\t87(1):\n\t\t\t\t\t1-\n\t\t\t\t\t9.\n\t\t\t\t\tDOI: 10.1016\/j.drugalcdep.2006.07.003. PubMed PMID: 16930857.","DOI":"10.1016\/j.drugalcdep.2006.07.003"},{"key":"2021110821353247200_i2168-9709-11-6-347-b62","doi-asserted-by":"crossref","unstructured":"Gonzalez\n              G,\n            \n            \n              Sevarino\n              K,\n            \n            \n              Sofuoglu\n              M,\n            \n            \n              Poling\n              J,\n            \n            \n              Oliveto\n              A,\n            \n            \n              Gonsai\n              K,\n            \n            et al.\n          \n          Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study.\n\t\t\t\t\tAddiction.\n\t\t\t\t\t2003;\n\t\t\t\t\t98(11):\n\t\t\t\t\t1625-\n\t\t\t\t\t32.\n\t\t\t\t\tDOI: 10.1046\/j.1360-0443.2003.00544.x. PubMed PMID: 14616189.","DOI":"10.1046\/j.1360-0443.2003.00544.x"},{"key":"2021110821353247200_i2168-9709-11-6-347-b63","doi-asserted-by":"crossref","unstructured":"Umbricht\n              A,\n            \n            \n              DeFulio\n              A,\n            \n            \n              Winstanley\n              EL,\n            \n            \n              Tompkins\n              DA,\n            \n            \n              Peirce\n              J,\n            \n            \n              Mintzer\n              MZ,\n            \n            et al.\n          \n          Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial.\n\t\t\t\t\tDrug Alcohol Depend.\n\t\t\t\t\t2014;\n\t\t\t\t\t140:\n\t\t\t\t\t92-\n\t\t\t\t\t100.\n\t\t\t\t\tDOI: 10.1016\/j.drugalcdep.2014.03.033. PubMed PMID: 24814607.","DOI":"10.1016\/j.drugalcdep.2014.03.033"},{"key":"2021110821353247200_i2168-9709-11-6-347-b64","doi-asserted-by":"crossref","unstructured":"Moran\n              LM,\n            \n            \n              Phillips\n              KA,\n            \n            \n              Kowalczyk\n              WJ,\n            \n            \n              Ghitza\n              UE,\n            \n            \n              Agage\n              DA,\n            \n            \n              Epstein\n              DH,\n            \n            et al.\n          \n          Aripiprazole for cocaine abstinence: a randomized-controlled trial with ecological momentary assessment.\n\t\t\t\t\tBehav Pharmacol.\n\t\t\t\t\t2017;\n\t\t\t\t\t28(1):\n\t\t\t\t\t63-\n\t\t\t\t\t73.\n\t\t\t\t\tDOI: 10.1097\/FBP.0000000000000268. PubMed PMID: 27755017.","DOI":"10.1097\/FBP.0000000000000268"},{"key":"2021110821353247200_i2168-9709-11-6-347-b65","doi-asserted-by":"crossref","unstructured":"Grabowski\n              J,\n            \n            \n              Rhoades\n              H,\n            \n            \n              Stotts\n              A,\n            \n            \n              Cowan\n              K,\n            \n            \n              Kopecky\n              C,\n            \n            \n              Dougherty\n              A,\n            \n            et al.\n          \n          Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials.\n\t\t\t\t\tNeuropsychopharmacology.\n\t\t\t\t\t2004;\n\t\t\t\t\t29(5):\n\t\t\t\t\t969-\n\t\t\t\t\t81.\n\t\t\t\t\tDOI: 10.1038\/sj.npp.1300392. PubMed PMID: 15039761.","DOI":"10.1038\/sj.npp.1300392"},{"key":"2021110821353247200_i2168-9709-11-6-347-b66","doi-asserted-by":"crossref","unstructured":"Handelsman\n              L,\n            \n            \n              Limpitlaw\n              L,\n            \n            \n              Williams\n              D,\n            \n            \n              Schmeidler\n              J,\n            \n            \n              Paris\n              P,\n            \n            \n              Stimmel\n              B.\n            \n          \n          Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients.\n\t\t\t\t\tDrug Alcohol Depend.\n\t\t\t\t\t1995;\n\t\t\t\t\t39(3):\n\t\t\t\t\t173-\n\t\t\t\t\t80.\n\t\t\t\t\tDOI: 10.1016\/0376-8716(95)01154-9. PubMed PMID: 8556965.","DOI":"10.1016\/0376-8716(95)01154-9"},{"key":"2021110821353247200_i2168-9709-11-6-347-b67","doi-asserted-by":"crossref","unstructured":"Handelsman\n              L,\n            \n            \n              Rosenblum\n              A,\n            \n            \n              Palij\n              M,\n            \n            \n              Magura\n              S,\n            \n            \n              Foote\n              J,\n            \n            \n              Lovejoy\n              M,\n            \n            et al.\n          \n          Bromocriptine for cocaine dependence. A controlled clinical trial.\n\t\t\t\t\tAm J Addict.\n\t\t\t\t\t1997;\n\t\t\t\t\t6(1):\n\t\t\t\t\t54-\n\t\t\t\t\t64.\n\t\t\t\t\tPubMed PMID: 9097872.","DOI":"10.3109\/10550499708993163"},{"key":"2021110821353247200_i2168-9709-11-6-347-b68","doi-asserted-by":"crossref","unstructured":"Schottenfeld\n              RS,\n            \n            \n              Pakes\n              JR,\n            \n            \n              Oliveto\n              A,\n            \n            \n              Ziedonis\n              D,\n            \n            \n              Kosten\n              TR.\n            \n          \n          Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse.\n\t\t\t\t\tArch Gen Psychiatry.\n\t\t\t\t\t1997;\n\t\t\t\t\t54(8):\n\t\t\t\t\t713-\n\t\t\t\t\t20.\n\t\t\t\t\tDOI: 10.1001\/archpsyc.1997.01830200041006. PubMed PMID: 9283506.","DOI":"10.1001\/archpsyc.1997.01830200041006"},{"key":"2021110821353247200_i2168-9709-11-6-347-b69","doi-asserted-by":"crossref","unstructured":"Schottenfeld\n              RS,\n            \n            \n              Chawarski\n              MC,\n            \n            \n              Pakes\n              JR,\n            \n            \n              Pantalon\n              MV,\n            \n            \n              Carroll\n              KM,\n            \n            \n              Kosten\n              TR.\n            \n          \n          Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.\n\t\t\t\t\tAm J Psychiatry.\n\t\t\t\t\t2005;\n\t\t\t\t\t162(2):\n\t\t\t\t\t340-\n\t\t\t\t\t9.\n\t\t\t\t\tDOI: 10.1176\/appi.ajp.162.2.340. PubMed PMID: 15677600.","DOI":"10.1176\/appi.ajp.162.2.340"},{"key":"2021110821353247200_i2168-9709-11-6-347-b70","doi-asserted-by":"crossref","unstructured":"Ling\n              W,\n            \n            \n              Hillhouse\n              MP,\n            \n            \n              Saxon\n              AJ,\n            \n            \n              Mooney\n              LJ,\n            \n            \n              Thomas\n              CM,\n            \n            \n              Ang\n              A,\n            \n            et al.\n          \n          Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.\n\t\t\t\t\tAddiction.\n\t\t\t\t\t2016;\n\t\t\t\t\t111(8):\n\t\t\t\t\t1416-\n\t\t\t\t\t27.\n\t\t\t\t\tDOI: 10.1111\/add.13375. PubMed PMID: 26948856; PubMed Central PMCID: PMC4940267.","DOI":"10.1111\/add.13375"},{"key":"2021110821353247200_i2168-9709-11-6-347-b71","doi-asserted-by":"crossref","unstructured":"Carroll\n              KM,\n            \n            \n              Nich\n              C,\n            \n            \n              Shi\n              JM,\n            \n            \n              Eagan\n              D,\n            \n            \n              Ball\n              SA.\n            \n          \n          Efficacy of disulfiram and twelve step facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial.\n\t\t\t\t\tDrug Alcohol Depend.\n\t\t\t\t\t2012;\n\t\t\t\t\t126(1-2):\n\t\t\t\t\t224-\n\t\t\t\t\t31.\n\t\t\t\t\tDOI: 10.1016\/j.drugalcdep.2012.05.019. PubMed PMID: 22695473.","DOI":"10.1016\/j.drugalcdep.2012.05.019"},{"key":"2021110821353247200_i2168-9709-11-6-347-b72","doi-asserted-by":"crossref","unstructured":"George\n              TP,\n            \n            \n              Chawarski\n              MC,\n            \n            \n              Pakes\n              J,\n            \n            \n              Carroll\n              KM,\n            \n            \n              Kosten\n              TR,\n            \n            \n              Schottenfeld\n              RS.\n            \n          \n          Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial.\n\t\t\t\t\tBiol Psychiatry.\n\t\t\t\t\t2000;\n\t\t\t\t\t47(12):\n\t\t\t\t\t1080-\n\t\t\t\t\t6.\n\t\t\t\t\tDOI: 10.1016\/s0006-3223(99)00310-8. PubMed PMID: 10862808.","DOI":"10.1016\/S0006-3223(99)00310-8"},{"key":"2021110821353247200_i2168-9709-11-6-347-b73","doi-asserted-by":"crossref","unstructured":"Kosten\n              TR,\n            \n            \n              Wu\n              GY,\n            \n            \n              Huang\n              W,\n            \n            \n              Harding\n              MJ,\n            \n            \n              Hamon\n              SC,\n            \n            \n              Lappalainen\n              J,\n            \n            et al.\n          \n          Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine \u03b2-hydroxylase.\n\t\t\t\t\tBiol Psychiatry.\n\t\t\t\t\t2013;\n\t\t\t\t\t73(3):\n\t\t\t\t\t219-\n\t\t\t\t\t24.\n\t\t\t\t\tDOI: 10.1016\/j.biopsych.2012.07.011. PubMed PMID: 22906516.","DOI":"10.1016\/j.biopsych.2012.07.011"},{"key":"2021110821353247200_i2168-9709-11-6-347-b74","doi-asserted-by":"crossref","unstructured":"Oliveto\n              A,\n            \n            \n              Poling\n              J,\n            \n            \n              Mancino\n              MJ,\n            \n            \n              Feldman\n              Z,\n            \n            \n              Cubells\n              JF,\n            \n            \n              Pruzinsky\n              R,\n            \n            et al.\n          \n          Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients.\n\t\t\t\t\tDrug Alcohol Depend.\n\t\t\t\t\t2011;\n\t\t\t\t\t113(2-3):\n\t\t\t\t\t184-\n\t\t\t\t\t91.\n\t\t\t\t\tDOI: 10.1016\/j.drugalcdep.2010.07.022. PubMed PMID: 20828943; PubMed Central PMCID: PMC3005977.","DOI":"10.1016\/j.drugalcdep.2010.07.022"},{"key":"2021110821353247200_i2168-9709-11-6-347-b75","doi-asserted-by":"crossref","unstructured":"Petrakis\n              IL,\n            \n            \n              Carroll\n              KM,\n            \n            \n              Nich\n              C,\n            \n            \n              Gordon\n              LT,\n            \n            \n              McCance-Katz\n              EF,\n            \n            \n              Frankforter\n              T,\n            \n            et al.\n          \n          Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts.\n\t\t\t\t\tAddiction.\n\t\t\t\t\t2000;\n\t\t\t\t\t95(2):\n\t\t\t\t\t219-\n\t\t\t\t\t28.\n\t\t\t\t\tDOI: 10.1046\/j.1360-0443.2000.9522198.x. PubMed PMID: 10723850.","DOI":"10.1046\/j.1360-0443.2000.9522198.x"},{"key":"2021110821353247200_i2168-9709-11-6-347-b76","doi-asserted-by":"crossref","unstructured":"Schottenfeld\n              RS,\n            \n            \n              Chawarski\n              MC,\n            \n            \n              Cubells\n              JF,\n            \n            \n              George\n              TP,\n            \n            \n              Lappalainen\n              J,\n            \n            \n              Kosten\n              TR.\n            \n          \n          Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment.\n\t\t\t\t\tDrug Alcohol Depend.\n\t\t\t\t\t2014;\n\t\t\t\t\t136:\n\t\t\t\t\t36-\n\t\t\t\t\t42.\n\t\t\t\t\tDOI: 10.1016\/j.drugalcdep.2013.12.007. PubMed PMID: 24462581.","DOI":"10.1016\/j.drugalcdep.2013.12.007"},{"key":"2021110821353247200_i2168-9709-11-6-347-b77","doi-asserted-by":"crossref","unstructured":"Poling\n              J,\n            \n            \n              Rounsaville\n              B,\n            \n            \n              Gonsai\n              K,\n            \n            \n              Severino\n              K,\n            \n            \n              Sofuoglu\n              M.\n            \n          \n          The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study.\n\t\t\t\t\tAm J Addict.\n\t\t\t\t\t2010;\n\t\t\t\t\t19(5):\n\t\t\t\t\t401-\n\t\t\t\t\t8.\n\t\t\t\t\tDOI: 10.1111\/j.1521-0391.2010.00066.x. PubMed PMID: 20716302.","DOI":"10.1111\/j.1521-0391.2010.00066.x"},{"key":"2021110821353247200_i2168-9709-11-6-347-b78","doi-asserted-by":"crossref","unstructured":"D\u00fcrsteler-Macfarland\n              KM,\n            \n            \n              Farronato\n              NS,\n            \n            \n              Strasser\n              J,\n            \n            \n              Boss\n              J,\n            \n            \n              Kuntze\n              MF,\n            \n            \n              Petitjean\n              SA,\n            \n            et al.\n          \n          A randomized, controlled, pilot trial of methylphenidate and cognitive-behavioral group therapy for cocaine dependence in heroin prescription.\n\t\t\t\t\tJ Clin Psychopharmacol.\n\t\t\t\t\t2013;\n\t\t\t\t\t33(1):\n\t\t\t\t\t104-\n\t\t\t\t\t8.\n\t\t\t\t\tDOI: 10.1097\/JCP.0b013e31827bfff4. PubMed PMID: 23277248.","DOI":"10.1097\/JCP.0b013e31827bfff4"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/11\/6\/347\/2955418\/i2168-9709-11-6-347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/11\/6\/347\/2955418\/i2168-9709-11-6-347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T11:24:03Z","timestamp":1731669843000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/11\/6\/article-p347.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":79,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,11,8]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2021.11.347","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}